List view / Grid view

Peter F. Lebowitz

 

news

Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib

Janssen Research & Development, LLC today announced the early stopping…

7 January 2014 | By Johnson & Johnson

Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA™ (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant…